Registration Successful...
null you have successfully logged registered and logged in
VACCINE EFFECTIVENESS

Offer fierce protection backed by years of vaccine effectiveness data, comparable to IIV2-12

Offer fierce protection backed by years of vaccine effectiveness data, comparable to IIV2-12

FLUMIST and IIV vaccine effectiveness data overlapped for all strains between the 2018 and the 2023 flu seasons2-12

Vaccine Effectiveness Chart
Vaccine Effectiveness Chart
Vaccine Effectiveness Chart
Vaccine Effectiveness Chart
Vaccine Effectiveness Chart

Data reflects LAIV4 which is relevant to LAIV because both vaccines use the same process and have overlapping compositions.1

There are no head-to-head clinical studies comparing LAIV4 and IIV. Results are descriptive only.

VE CIs are truncated at -100 to enable graphical display.

✝Data for interim influenza A only; A(H3N2) represented 97% of all circulating strains.

§A(H3N2) represented an estimated 94% of all influenza positive participants.

DEN=Denmark; FIN=Finland; IIV=inactivated influenza vaccine; LAIV4=quadrivalent live attenuated influenza vaccine; LAIV=live attenuated influenza vaccine; mo=months; n=total number of cases; NA=not available; VE=vaccine effectiveness; UK=United Kingdom; US=United States; yrs=years; CI=confidence interval.

IMPORTANT SAFETY INFORMATION

  • Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
  • Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of the potential benefits and risks
  • The effectiveness of FLUMIST has not been studied in immunocompromised persons
  • The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUMIST
  • FLUMIST may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children ages 2-6 years), and sore throat (adult ages 18-49 years)

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

Please see full Prescribing Information for FLUMIST, including Patient Information.

You may report side effects related to AstraZeneca products.